VistaGen Therapeutics, Inc. ROE

ROE of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2020 was -3294.6% (a 795.3% increase from previous year)
  • Annual ROE for 2019 was -367.99% (a -11.11% decrease from previous year)
  • Annual ROE for 2018 was -414.0% (a -142.24% decrease from previous year)
  • Twelve month ROE ending December 30, 2020 was -37.29% (a -99.36% decrease compared to previous quarter)
  • Twelve month trailing ROE decreased by -98.87% year-over-year
Trailing ROE for the last four month:
30 Dec '20 29 Sep '20 29 Jun '20 30 Mar '20
-37.29% -5814.41% 950.88% -3294.72%
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of VistaGen Therapeutics, Inc.

Most recent ROEof VTGN including historical data for past 10 years.

Interactive Chart of ROE of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 -3294.6%
2019 -367.99%
2018 -414.0%
2017 980.11%
2016 437.11%
2015 83.29%
2014 23.41%
2013 252.75%
2012 63.28%
2011 57.67%
2010 1636.36%

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.